中文 - EN
Home > News > META Pharmaceuticals Selected as one of the Top 100 High Growth Enterprises in the Greater Bay Area 2023
META Pharmaceuticals Selected as one of the Top 100 High Growth Enterprises in the Greater Bay Area 2023
2023/11/02

On October 27, 2023, the 2023 Greater Bay Area Innovation and Economy Forum was grandly opened in Shenzhen. The event was organized by the Southern Finance and Economy All Media Group and co-organized by the 21st Century Business Herald, the Guangdong-Hong Kong-Macao Greater Bay Area Research Institute, and the Social Value Investment Alliance (Shenzhen).

Centered around innovation economy catalysts within the three major economic drivers, the conference invited industry leaders to explore fresh opportunities for sustainable development in the Bay Area. The event featured a main forum and three roundtable dialogues. Simultaneously, the Shenzhen Venture Capital Association and the Guangdong-Hong Kong-Macao Greater Bay Area Research Institute jointly unveiled the final list of the ‘2023 Guangdong, Hong Kong, and Macao Greater Bay Area Top 100 High Growth Enterprises.’

The ‘2023 Top 100 High Growth Enterprises in the Greater Bay Area’ list focuses on five major industrial tracks within the Greater Bay Area: new-generation information technology, digital economy, new energy/new materials, biomedicine and health, and advanced manufacturing. The list aims to identify and recognize outstanding high-growth enterprises in the Greater Bay Area. By establishing criteria related to innovation and high growth, the list comprehensively evaluates new industries, technologies, business forms, and models. It fully showcases the exceptional high-growth enterprises in the Bay Area, serving as a benchmark for the dynamic industries within the region.

Shenzhen Moyuan Biotechnology Co., Ltd. (META Pharmaceuticals) was honored to be selected as one of the Top 100 High Growth Enterprises in the Greater Bay Area for 2023. This recognition is a testament to its outstanding development status and significant growth potential within the biomedical and health sector. META Pharmaceuticals underwent rigorous evaluation by experts at various levels to achieve this distinction.

We are very happy to receive this honor, and at the same time, we have more enthusiasm and motivation to continue to move forward.